Payer and Patient Education Considerations for SCLC

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Anne Chiang, MD, PhD

Key Takeaways

Establishing clear communication with payers and providing comprehensive clinical evidence can facilitate medication access for SCLC patients.
Utilizing educational materials from reputable cancer organizations and support groups enhances patient understanding of SCLC.
Tailoring information to individual patient needs and encouraging active participation in treatment plans are essential for effective patient education.

Panelists discuss how to effectively collaborate with payers to ensure access to necessary medications for patients with small cell lung cancer (SCLC), while also exploring best practices for patient education and identifying valuable resources to share with those diagnosed with SCLC.

EP: 1.Introduction: Risk Factors and Characteristics Defining SCLC

EP: 2.Established Multidisciplinary Therapies for SCLC

EP: 3.Immunotherapies for Extensive-Stage SCLC

EP: 4.Introducing Bispecifics for Extensive-Stage SCLC

EP: 5.Standard of Care Durvalumab for Limited-Stage SCLC

EP: 6.Additional Immunotherapies on the Horizon for LS-SCLC

Now Viewing

EP: 7.Payer and Patient Education Considerations for SCLC

EP: 8.Biomarker Discovery and Exploration for SCLC

EP: 9.Key Takeaways on Recent Advances in SCLC

EP: 10.Therapies Beyond the Front Line for SCLC

EP: 11.Timing and Urgency Considerations in SCLC

What are best practices for working with payers to ensure that patients with small cell lung cancer (SCLC) get access to the necessary medications?

How do you educate patients about SCLC, and which resources do you find useful in sharing with patients?